Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

Inclusion Criteria: * Receiving insulin for the treatment of documented diagnosis of T1DM for at least 2 years * Body Mass Index (BMI) of 18.5 kg/m2 to 35.0 kg/m2 * On treatment with a stable insulin regimen for at least 8 weeks * Currently using a continuous glucose monitoring (CGM) system * HbA1c less than or equal to 10.0% * Females of non-childbearing potential must be ≥1 year post-menopausal or documented as being surgically sterile. Females of childbearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product * Male subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 3 months after the end of the treatment period * Other inclusion criteria may apply. Exclusion Criteria: * History of type 2 diabetes, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis * Pancreas, pancreatic islet cells, or renal transplant recipient * T1DM treatment with any other antihyperglycemic drug (e.g., metformin, alpha- glucosidase inhibitors, SGLT-2 inhibitors, pramlintide, inhaled insulin, pre-mixed insulins, etc.) within 30 days of Day 1 * Occurrence of severe hypoglycemia involving coma and/or seizure that required hospitalization or hypoglycemia-related treatment by an emergency physician or paramedic within 3 months prior to Day 1 * Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident ≤12 weeks * Indication of liver disease * Current signs and symptoms of anemia * Untreated eating disorders such as bulimia or anorexia nervosa * History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia (MEN) or family history of MEN. * Treatment with systemic corticosteroids within 30 days of Day 1, or planned initiation of such therapy during the study. * Medical history of cancer or treatment for cancer in the last five years * Women who are pregnant, nursing, or who plan to become pregnant while in the trial * Other exclusion criteria may apply